IL6 and chronic kidney disease: Other human in vitro studies describe a role of SDMA in inducing vascular damage through increased reactive oxygen species (ROS) production by monocytes [30] and involvement in the inflammatory process of CKD by activating NF‐κB, subsequently resulting in enhanced expression of IL‐6 and TNF‐α [31].